EBV cells-to-LAMP assay is compatible with a point-of-care approach. (A) FNA samples obtained from EBV+ cell line xenografts in mice were tested using cells-to-LAMP followed by analysis with TINY (left), with representative cells-to-LAMP results output by TINY software of EBV+ and EBV- cell lines shown (top right). The blue bars in this image indicate the 4 EBV+ cell lines that amplified before the threshold time. Four independent aspirates were taken from each of 2 tumors per cell line (bottom right). NA denotes that the negative control cell line, Ramos, was not amplifiable. (B) Fresh tonsil specimens were used to perform an ex vivo FNA with cells-to-LAMP followed by TINY. Tissue specimens from 3 EBV+ lymphoma specimens were used for DNA extraction and tested in parallel by LAMP and analyzed with TINY. These included 2 non-Hodgkin lymphomas (NHL1 and NHL 2) and a classical Hodgkin lymphoma (cHL 3). Results are from a representative experiment with triplicate reactions for each sample, out of 6 to 8 independent experiments for each specimen (data shown in aggregate in supplemental Figure 1 and supplemental Table 2). All “undetermined” values, meaning no amplification, were falsely set to 40 minutes for the purpose of visualization and averaging. (C) EBER in situ hybridization was performed to evaluate positivity for EBV in the tonsil specimens. A representative example from tonsil 7 is shown. Original magnification is ×10.